Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

Phase III Clinical Trial

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma, Melanoma
Trial Number: 06246916
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations